Karen Lockheart

Karen Lockheart practices at High Desert Medical Group in Lancaster, California.

Karen Lockheart's NPI, 1831638824, was assigned on February 23, 2017. Karen Lockheart holds California license 95006180.

Karen Lockheart's primary practice is High Desert Medical Group, at 43839 15th W St, Lancaster, CA 93534. The practice phone is (661) 945-5984.

Karen Lockheart's primary practice is High Desert Medical Group in Lancaster, California. The medical group on file is High Desert Medical Group. Dmand AI also links Karen Lockheart to 1 more group practice or clinic, named with a free account. Karen Lockheart's employer is on file too: an urgent care center.

Dmand AI tracks the electronic health record (EHR) system at each site where Karen Lockheart practices, 2 sites in all. Vendor and product names are available with a free account.

Family is Karen Lockheart's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Karen Lockheart is licensed in California.

CMS data shows 77 Medicare services from Karen Lockheart across 1 procedure code in 2024, all of them office visits, for 41 Medicare patients. Medicare paid $4,533 for them. Every service was in an office.

CMS counts 41 Medicare patients who saw Karen Lockheart in 2024. The largest group is 65 to 74, with 20 patients. 75% of them have high cholesterol, and 61% have high blood pressure. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Karen Lockheart's median patient age at 74, with 62% women.

In 2024, Karen Lockheart wrote 998 Medicare Part D claims for 250 patients. 89% of them were for generic drugs. CMS names the drug for 695 of them, across 33 drugs with 11 or more claims each, at $61,424 in total drug cost.

Karen Lockheart accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 36 general payments to Karen Lockheart from 13 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $224.